[求助]请问谁了解唯美生, 小细胞肺癌脑转移可不可以用?跪谢!
RT <p><span style="FONT-SIZE: 8pt; COLOR: #666666; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: 宋体;"><font face="仿宋_GB2312" size="3">如有用过唯美生的小细胞病友，希望加入讨论啊！</font></span></p><p><span style="FONT-SIZE: 8pt; COLOR: #666666; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: 宋体;"><a href="http://www.51qiji.com/dispbbs.asp?boardid=1&replyid=798&id=144&page=1&skin=0&Star=10">http://www.51qiji.com/dispbbs.asp?boardid=1&replyid=798&id=144&page=1&skin=0&Star=10</a></span></p> <p>我查到的一些资料:</p><p><table cellspacing="0" cellpadding="0" width="100%" border="0" style="WIDTH: 100%; mso-cellspacing: 0cm; mso-padding-alt: 0cm 0cm 0cm 0cm;"><tbody><tr style="HEIGHT: 18.75pt;"><td width="803" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; WIDTH: 602.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; HEIGHT: 18.75pt; BACKGROUND-COLOR: transparent;"><p class="MsoNormal" align="center" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt; TEXT-ALIGN: center;"><strong><span style="COLOR: #687820; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">晚期肺癌新疗法：放射免疫靶向治疗</span></strong><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></p></td></tr><tr style="HEIGHT: 15pt;"><td width="803" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; WIDTH: 602.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; HEIGHT: 15pt; BACKGROUND-COLOR: transparent;"><p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt;"><font face="Times New Roman"> <span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></font></p></td></tr><tr><td width="803" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; WIDTH: 602.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; BACKGROUND-COLOR: transparent;"><div align="center"><table cellspacing="1" cellpadding="0" width="97%" bgcolor="#ebf0f5" border="0" style="BACKGROUND: #ebf0f5; WIDTH: 97%; mso-cellspacing: .7pt; mso-padding-alt: 0cm 0cm 0cm 0cm;"><tbody><tr style="HEIGHT: 48.75pt;"><td style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; BACKGROUND: #f7fafd; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; HEIGHT: 48.75pt;"><p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt;"><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><font face="Times New Roman"> <br/><br/> </font></span><span style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">南京东南大学肿瘤研究所所长、中大医院临床肿瘤中心主任李苏宜教授日前介绍说，放射免疫靶向治疗是继肿瘤化疗和放射治疗后又一全新的治疗方法，被称为“生物导弹”。该方法结合了单克隆抗体的靶向与放射性核素内照射的强杀伤作用，具有疗效好、副作用低的特点。</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><font face="Times New Roman"><p></p></font></span></p><p style="LINE-HEIGHT: 15.75pt;"><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 据李苏宜教授介绍，今年</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">1</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">月</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">14</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">日，肺癌放射免疫靶向治疗新成果——碘－</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">131</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">肿瘤细胞核人鼠嵌合单克隆抗体，经国家食品药品监督管理局批准，作为治疗晚期肺癌的新方法开始应用于临床。</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></p><p style="LINE-HEIGHT: 15.75pt;"><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 所谓单克隆抗体如同一匹识途的马，碘－</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">131</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">是一种放射治疗的“武器”，放射免疫靶向治疗就像让这匹携带放射治疗武器的马，直冲满是肿瘤的敌区，从内部对肿瘤组织实施打击。将其注射到患者体内后，它可以随着血液循环来到肿瘤部位，甚至是肿瘤乏氧区，与肿瘤内部坏死区暴露出来的组蛋白结合，同时碘－</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">131</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">发射射线，杀死其周围的肿瘤活细胞，并形成新的肿瘤坏死区。这样周而复始，使肿瘤坏死区不断扩大，由内向外摧毁肿瘤，达到治疗目的，因此它又被称为“肿瘤坏死疗法”。</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></p><p style="LINE-HEIGHT: 15.75pt;"><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 进入</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">21</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">世纪，靶向治疗引发了抗癌治疗理念的变革。这些靶向药物的应用，将原来晚期恶性肿瘤的疗效提高了</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">2</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">～</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">5</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">倍。靶向治疗包含两层含意：抗肿瘤药物有选择地作用于肿瘤细胞的某些靶点，而这些靶点在正常细胞上没有或很少；药物主要杀伤肿瘤细胞，而对正常细胞没有影响或影响很小。临床试验表明，放射免疫靶向治疗对放化疗失败的小细胞肺癌的有效率为</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">50</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">％，治疗放化疗失败的非小细胞肺癌总有效率为</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">33</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">％，鳞癌的有效率为</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">46.2</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">％，腺癌的有效率为</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">24</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">％，平均生存期可达到</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">11.7</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">个月。而传统化疗对放化疗不能控制或复发的晚期肺癌的疗效较差，一般有效率在</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">10</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">％左右，平均生存期在</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">7</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">～</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";">8</span><span style="FONT-SIZE: 9pt; COLOR: #687820; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">个月。</span><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></p></td></tr></tbody></table></div><p class="MsoNormal" style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15.75pt;"><span lang="EN-US" style="FONT-SIZE: 9pt; COLOR: #687820; FONT-FAMILY: " ";"><p></p></span></p></td></tr></tbody></table></p> <div align="center"><table cellspacing="0" cellpadding="0" width="97%" border="0" style="WIDTH: 97%; mso-cellspacing: 0cm; mso-padding-alt: 0cm 0cm 0cm 0cm;"><tbody><tr style="HEIGHT: 22.5pt;"><td valign="bottom" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; HEIGHT: 22.5pt; BACKGROUND-COLOR: transparent;"><p class="MsoNormal" align="center" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center;"><span class="biaoti151"><span style="FONT-SIZE: 15pt; FONT-FAMILY: 宋体; LETTER-SPACING: 0pt; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"><strong>全球首个肺癌放射免疫治疗新药唯美生成功上市</strong></span></span><font face="Times New Roman"><span style="COLOR: black; FONT-FAMILY: " ";">
</span><span lang="EN-US" style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: " ";"><p></p></span></font></p></td></tr><tr style="HEIGHT: 22.5pt;"><td valign="bottom" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; HEIGHT: 22.5pt; BACKGROUND-COLOR: transparent;"><p class="MsoNormal" align="center" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center;"><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">发表：</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">(2007-05-31 07:58); </font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">最后修改</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">:2007-05-31 07:58; </font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">栏目：</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">[</font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">新药资讯</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">] <br/></font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">作者：</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">; </font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">【阅读：</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">397</font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">】</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman"> <shapetype id="_x0000_t75" stroked="f" filled="f" path="m@4@5l@4@11@9@11@9@5xe" opreferrelative="t" ospt="75" coordsize="21600,21600"><stroke joinstyle="miter"></stroke><formulas><f eqn="if lineDrawn pixelLineWidth 0"></f><f eqn="sum @0 1 0"></f><f eqn="sum 0 0 @1"></f><f eqn="prod @2 1 2"></f><f eqn="prod @3 21600 pixelWidth"></f><f eqn="prod @3 21600 pixelHeight"></f><f eqn="sum @0 0 1"></f><f eqn="prod @6 1 2"></f><f eqn="prod @7 21600 pixelWidth"></f><f eqn="sum @8 21600 0"></f><f eqn="prod @7 21600 pixelHeight"></f><f eqn="sum @10 21600 0"></f></formulas><path oconnecttype="rect" gradientshapeok="t" oextrusionok="f"></path><lock aspectratio="t" vext="edit"></lock></shapetype></font><shape id="_x0000_i1026" alt="" type="#_x0000_t75" style="WIDTH: 9pt; HEIGHT: 6.75pt;"></shape></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">【</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><a href="http://www.daifumd.com/_daifumd/blog/html/816/javascript:"><b><span style="FONT-SIZE: 12pt; COLOR: red; FONT-FAMILY: 宋体; LETTER-SPACING: 0pt; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">留言</span></b></a></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">】</span><span style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">
</font></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">【</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><a href="http://www.daifumd.com/_daifumd/blog/html/816/javascript:"><b><span style="FONT-SIZE: 12pt; COLOR: purple; FONT-FAMILY: 宋体; LETTER-SPACING: 0pt; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">繁體</span></b></a></span><span style="COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">】</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman">
<p></p></font></span></p><div class="MsoNormal" align="center" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center;"><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><font face="Times New Roman"><hr align="center" width="100%" size="1"/></font></span></div><p class="MsoNormal" align="center" style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center;"><span lang="EN-US" style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: " ";"><p><font face="Times New Roman"></font></p></span></p></td></tr><tr><td valign="top" style="BORDER-RIGHT: #d4d0c8; PADDING-RIGHT: 0cm; BORDER-TOP: #d4d0c8; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: #d4d0c8; PADDING-TOP: 0cm; BORDER-BOTTOM: #d4d0c8; BACKGROUND-COLOR: transparent;"><p><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"> </span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">全球首个肺癌放射免疫治疗新药唯美生成功上市 </span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 肺癌是全球第一的癌症杀手，每年全球新增病例</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">120</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">万人，每</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">30</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">秒就有一人死于肺癌。在中国，肺癌同样是发病率与死亡率最高的癌症，也是癌症防治工作中的重中之重。长期以来，外科手术、放射治疗虽然在控制肿瘤的局部病灶方面有很好的疗效，但是预防肿瘤的复发、转移却显得无能为力。由于肺癌发病隐匿，一旦发现常常已经失去手术机会，化疗因此就成了一个重要的手段，但是化疗对人体健康的危害较大，处于肺癌晚期的患者常常因无法耐受化疗的痛苦而放弃治疗。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 随着单克隆抗体技术的崛起，放射标记的单克隆抗体已经应用于临床，开辟了一种治疗癌症的新方法——放射免疫治疗（</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">radioimmunotherapy,RIT</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">）。放射性同位素标记的抗肿瘤抗体，注射入体内，抗体与相应的肿瘤抗原结合，从而将放射性同位素锁定在肿瘤部位，放射性同位素持续的内放射，最终造成肿瘤细胞坏死。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 目前，全球仅有两个放射免疫治疗药物，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">90Y-ibritumomab(Zevalin)</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">和</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">131I-tositumomab(Bexxar)</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">经美国</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">FDA</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">批准用于淋巴瘤的治疗。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">Zevalin</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">和</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">Bexxar</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">在欧美已经开始广泛应用，为淋巴瘤的治疗提供了一种有力武器，年销售额近</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">10</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">亿美金。我们有理由相信，在不久的将来，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">RIT</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">会成为继肿瘤放、化疗后，肿瘤分子靶向治疗和内放射治疗完美结合的全新治疗方法。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";"> 虽然</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">RIT</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">在淋巴瘤的治疗中取得了如此显著的疗效，但是它对于实体瘤的疗效却一直差强人意。主要原因是实体瘤对放射线本来就不大敏感。同时，在传统的</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";">RIT</span><span style="COLOR: black; mso-ascii-font-family: " "; mso-hansi-font-family: " ";">中一般都采用膜抗原单抗。这就引来了一系列问题。首先，特定的膜抗原并不是在所有的肿瘤细胞上表达。也就是说，同样是肺癌，会有很多的病理类型，不同的病理类型肿瘤的抗原标志物会有差异。即使是相同病理类型，由于肿瘤细胞的异质性，抗原的表达也会不同。而且结合的抗体也经常会因为膜抗原的降解及内吞，从结合部位脱落。以上原因都会造成肿瘤部位放射剂量的相对不足或是抗体对肿瘤缺乏特异的靶向作用，从而造成治疗的失败。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: " ";"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';"> </span></p></td></tr></tbody></table></div> 正是在这样的背景之下，<span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">TNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">（肿瘤坏死疗法）抗体应运而生。虽然</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">TNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">抗体的研发过程充满了艰辛和挫折，但最终还是成功的攻克了</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">RIT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">在治疗实体瘤方面的难题。公司经八年研发推出的治疗肺癌新药——唯美生（碘</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">肿瘤细胞核嵌合单抗注射液），日前在中国召开了上市会，成功上市，进入中国市场。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';"><p></p></span><p><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';"> </span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131I-chTNT(</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">唯美生</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">)</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">经中国</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">SFDA</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">批准用于放化疗失败的晚期肺癌治疗。唯美生的上市为广大一线治疗失败的晚期肺癌患者提供了一种新的生命希望。据唯美生的主要研制者美国南加州大学医学院</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">Alan L.Epstein</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">教授介绍，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">TNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">抗体仅锁定实体瘤的变性坏死组织，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131I-chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">与肿瘤细胞核抗原结合，与单抗</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">结合的放射性核素对坏死区边缘的肿瘤活细胞进行杀伤，造成新的坏死，接着单抗</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">扩展到新的坏死区，周而复始使肿瘤坏死区不断扩大，由内向外摧毁肿瘤，达到治疗目的。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';"> 目前晚期肺癌的治疗有效率仅有</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">10</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">％，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">5</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">年生存率小于</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">1</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">％，大多数患者得不到有效治疗。据悉，</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131I-chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">治疗肺癌的</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">II</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">期临床试验中，晚期肺癌的病人接受了</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131I-chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">的注射，注射途径为静脉注射或肿瘤局部注射，总有效率为</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">34.6%</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">。该临床试验证明</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';">131I-chTNT</span><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';">治疗肺癌是有效的，而且其副作用也是可以耐受的。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';"><p></p></span></p><p><span style="COLOR: black; mso-ascii-font-family: ' '; mso-hansi-font-family: ' ';"> 唯美生在中国上市，为中国人带来了一种新的治疗肺癌的选择，给广大晚期肺癌患者带来了希望。</span><span lang="EN-US" style="COLOR: black; FONT-FAMILY: ' ';"><p></p></span></p> <font size="4">不相信此药。</font> <div class="msgheader">QUOTE:</div><div class="msgborder"><b>以下是引用<i>无香</i>在2007-8-27 20:27:05的发言：</b><br/><font size="4">不相信此药。</font></div><p>为什么不相信?</p>
页:
[1]